文献速递外周动脉疾病

药物洗脱支架治疗腹股沟下旁路移植血管狭窄的中期结局更优

Drug-Eluting Stents are Associated with Superior Mid-Term Outcomes for the Treatment of Infrainguinal Bypass Graft Stenoses.
PubMed 文献 · Ann Vasc Surg · 2022-07-08

该回顾性研究比较了依维莫司药物洗脱支架(eDES)、普通球囊血管成形术(PTA)、经皮切割球囊(PCB)和药物涂层球囊(DCB)治疗腹股沟下旁路移植血管狭窄的中期结局,纳入72例患者共152处狭窄。结果显示eDES组24个月一期通畅率显著优于其他方式,风险调整后eDES与PTA相比一期通畅丧失风险最低(HR 0.15,95%CI 0.05-0.47),作者认为eDES应被视为主要治疗方式。

要点

  • eDES组24个月一期通畅率72.9%(95%CI 49.8-85.6),优于PCB、PTA和DCB组(P=0.03)。
  • 风险调整后eDES与PTA相比,一期通畅丧失风险HR为0.15(95%CI 0.05-0.47)。
  • 作者认为eDES应被视为腹股沟下旁路移植血管狭窄的主要治疗方式。

核心结论

  • eDES与其他腔内技术相比与更优的24个月通畅率相关,作者认为其应被视为腹股沟下旁路移植血管狭窄的主要治疗方式。

研究设计与样本

  • 回顾性综述,纳入2010年8月至2021年8月期间因腹股沟下旁路移植血管狭窄接受腔内介入治疗的患者,共72例连续患者、152处离散狭窄。
  • 采用Kaplan-Meier曲线及log-rank检验比较各组结局,并用Cox比例风险模型校正组间基线差异。

主要发现

  • 152处病变中,PTA治疗44.1%(n=67),PCB治疗17.8%(n=27),DCB治疗20.4%(n=31),eDES治疗17.8%(n=27)。
  • 中位随访28.5个月(四分位距11.5-51.9);各组在旁路构型、导管选择或狭窄位置(近端吻合口、旁路中段、远端吻合口)方面无差异。
  • 介入后24个月一期通畅率eDES组为72.9%(95%CI 49.8-85.6),PCB组为55.9%(95%CI 34.2-72.9),PTA组为34.4%(95%CI 21.7-47.4),DCB组为33.6%(95%CI 14.5-53.9)(P=0.03)。
  • 一期辅助通畅率、保肢率和死亡率在各方式间无显著差异(P>0.05)。
  • 风险调整后,eDES与PTA相比一期通畅丧失风险最低(HR 0.15,95%CI 0.05-0.47)。

临床怎么用

  • 作者认为eDES应被视为腹股沟下旁路移植血管狭窄的主要治疗方式。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously demonstrated that everolimus drug-eluting stents (eDES) have reasonable short-term patency for the treatment of infrainguinal bypass stenoses. The aim of this study is to compare mid-term outcomes of eDES, plain balloon angioplasty (PTA), percutaneous cutting balloon (PCB), and drug-coated balloon (DCB) interventions for failing infrainguinal bypasses. METHODS: We conducted a retrospective review of patients with infrainguinal bypass stenoses treated by endovascular intervention (August 2010-August 2021). The primary outcome was primary patency (PP). Secondary outcomes were primary-assisted patency (PAP), secondary patency (SP), limb salvage (LS), and mortality. Outcomes were compared by treatment using Kaplan-Meier curves with log-rank tests and Cox proportional hazards models adjusting for baseline differences between groups. RESULTS: Seventy-two consecutive patients with 152 discrete infrainguinal bypass graft stenoses were identified. Mean age was 65.1 ± 10.6 years, 55.6% were male, and 48.6% were Black. In total, 81.9% of patients were originally treated for chronic limb-threatening ischemia, and 57.2% of distal anastomoses were to tibial or pedal targets. Of 152 lesions, 44.1% (n = 67) were treated with PTA, 17.8% (n = 27) with PCB, 20.4% (n = 31) with DCB, and 17.8% (n = 27) with eDES. Median follow-up was 28.5 months (interquartile range 11.5-51.9). There was no difference in bypass configuration, conduit choice, or stenosis location (proximal anastomosis, mid-bypass, distal anastomosis) between groups. At 24 months postintervention, PP was significantly better for eDES (72.9%, 95% confidence interval [CI] 49.8-85.6), followed by PCB (55.9%, 95% CI 34.2-72.9), PTA (34.4%, 95% CI 21.7-47.4), and DCB (33.6%, 95% CI 14.5-53.9) (P = 0.03). PAP, LS, and mortality did not significantly differ between modalities (P > 0.05). After risk adjustment, eDES was associated with the lowest risk of PP loss (hazard ratio versus PTA 0.15, 95% CI 0.05-0.47). CONCLUSIONS: eDES is associated with superior 24-month patency rates compared to other endovascular technologies, and should be considered a primary therapy modality for the treatment of infrainguinal bypass graft stenoses.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hicks CW, Stonko DP, Deery SE, et al. Drug-Eluting Stents are Associated with Superior Mid-Term Outcomes for the Treatment of Infrainguinal Bypass Graft Stenoses. Ann Vasc Surg. 2022. PMID: 35817388. doi:10.1016/j.avsg.2022.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。